免疫检查点抑制剂致多系统免疫相关不良事件的诊疗思路

doi:10.12114/j.issn.1007-9572.2022.0585

中国全科医学 ›› 2023, Vol. 26 ›› Issue (23): 2930-2935.DOI: 10.12114/j.issn.1007-9572.2022.0585

所属专题：用药最新文章合辑

免疫检查点抑制剂致多系统免疫相关不良事件的诊疗思路

张彦景¹, 宋晓坤²^,^*()

1．050031　河北省石家庄市，河北医科大学第一医院药学部
2．300201　天津市，天津医科大学肿瘤医院药学部

收稿日期:2022-08-04 修回日期:2022-09-19 出版日期:2023-08-15 发布日期:2022-09-30
通讯作者: 宋晓坤
作者贡献：张彦景负责病例资料的收集、文献检索、论文撰写及修订，对文章负责；宋晓坤负责文章内容的审校。

Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors

ZHANG Yanjing¹, SONG Xiaokun²^,^*()

1. Department of Pharmacy, the First Hospital of Hebei Medical University, Shijiazhuang 050031, China
2. Department of Pharmacy, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300201, China

Received:2022-08-04 Revised:2022-09-19 Published:2023-08-15 Online:2022-09-30
Contact: SONG Xiaokun

分享到

摘要/Abstract

摘要： 免疫检查点抑制剂（ICIs）作为一类新型抗癌疗法改变了多种癌症的治疗格局。然而，ICIs存在许多潜在的并发症，称之为免疫相关不良事件（irAEs），可能涉及神经系统、心脏系统、肺系统、皮肤系统、肾脏系统、胃肠系统、肝脏系统和血液系统等。尽管国内外已出台了一系列irAEs管理指南，但是临床医生对此疾病的认知水平和重视程度不同，在临床工作中对irAEs的早期识别、诊断及治疗还不够规范。本文报道了1例使用信迪利单抗治疗后患者出现严重的多系统irAEs的临床资料，结合相关文献对病例进行分析，总结值得借鉴的经验以及存在的局限，为临床医生更好地处理多系统irAEs提供思路。

关键词: 免疫检查点抑制剂, 糖皮质激素, 免疫抑制剂, 多系统, 免疫相关不良事件, 信迪利单抗, 诊疗思路

Abstract:

As a new type of anti-cancer therapy, immune checkpoint inhibitors (ICIs) have transformed the treatment of various cancers. However, ICIs are associated with many potential complications, namely immune-related adverse events (irAEs) , possibly involving the nervous, cardiac, pulmonary, cutaneous, renal, gastrointestinal, hepatic, and hematologic systems. Although a series of guidelines for the management of irAEs have been issued, early identification, diagnosis and treatment of irAEs in clinical practice are still not standardized enough due to different levels of awareness and attention regarding the disease across clinicians. We analyzed the clinical data of a patient with severe multisystem irAEs developed after treatment with cindilimab, and reviewed relevant literature, then summarized the benefits and limitations of treatments for irAEs, providing ideas for better managing multisystem irAEs clinically.

Key words: Immune checkpoint inhibitors, Glucocorticoids, Immunosuppressive agents, Multiorgan, Immune-related adverse events, Sintilimab, Diagnosis and treatment ideas

张彦景,宋晓坤. 免疫检查点抑制剂致多系统免疫相关不良事件的诊疗思路[J]. 中国全科医学, 2023, 26(23): 2930-2935. DOI: 10.12114/j.issn.1007-9572.2022.0585.
ZHANG Yanjing,SONG Xiaokun. Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors[J]. Chinese General Practice, 2023, 26(23): 2930-2935. DOI: 10.12114/j.issn.1007-9572.2022.0585.

图/表 3

图1 白细胞和中性粒细胞计数变化注：WBC=白细胞，NE=中性粒细胞。

Figure 1 Changes in white blood cell and neutrophil counts between October 26 and November 28，2021

图2 肝功能指标变化注：ALT=丙氨酸氨基转移酶，AST=天冬氨酸氨基转移酶。

Figure 2 Changes in levels of liver function indicators between October 26 and November 28，2021

图3 心脏生物标志物高敏肌钙蛋白变化注：hsTnI=高敏肌钙蛋白。

Figure 3 Changes in the level of high-sensitivity cardiac troponin between November 16 and 28，2021

参考文献 21

[1]	CHHABRA N, KENNEDY J. A review of cancer immunotherapy toxicity：immune checkpoint inhibitors[J]. J Med Toxicol，2021，17(4):411-424. DOI：10.1007/s13181-021-00833-8.
[2]	国家食品药品监督管理局.抗肿瘤治疗的免疫相关不良事件评价技术指导原则[Z]. [2022-05-16].
[3]	中国临床肿瘤学会. 免疫检查点抑制剂相关毒性管理指南[M].北京：人民卫生出版社，2021：28.
[4]	ZHANG L L, ZLOTOFF D A, AWADALLA M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis[J]. Circulation，2020，141(24):2031-2034. DOI：10.1161/CIRCULATIONAHA.119.044703.
[5]	CHEN Y K, JIA Y J, LIU Q H, et al. Myocarditis related to immune checkpoint inhibitors treatment：two case reports and literature review[J]. Ann Palliat Med，2021，10(7):8512-8517. DOI：10.21037/apm-20-2620.
[6]	AOKI K, HAMAMOTO T, CHIKUIE N, et al. Severe multiple simultaneous immune-related adverse events in a patient with head and neck cancer[J]. Auris Nasus Larynx，2023，50(2):309-313. DOI：10.1016/j.anl.2022.02.002.
[7]	MAHMOOD S S, FRADLEY M G, COHEN J V, et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol，2018，71(16):1755-1764. DOI：10.1016/j.jacc.2018.02.037.
[8]	KURIMOTO C, INABA H, ARIYASU H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors[J]. Cancer Sci，2020，111(5):1468-1477. DOI：10.1111/cas.14363.
[9]	国家卫生计生委印发抗菌药物临床应用指导原则（2015年版）[J]. 中国医药生物技术，2015，10(5):477.
[10]	BAI J, LI D, YANG P D, et al. Camrelizumab-related myocarditis and myositis with myasthenia gravis：a case report and literature review[J]. Front Oncol，2022，11:778185. DOI：10.3389/fonc.2021.778185.
[11]	YANASE T, MORITOKI Y, KONDO H, et al. Myocarditis and myasthenia gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma：a case report of successful management[J]. Urol Case Rep，2020，34:101508. DOI：10.1016/j.eucr.2020.101508.
[12]	SAFA H, JOHNSON D H, TRINH V A, et al. Immune checkpoint inhibitor related myasthenia gravis：single center experience and systematic review of the literature[J]. J Immunother Cancer，2019，7(1):319. DOI：10.1186/s40425-019-0774-y.
[13]	LEE D J, LEE H J Jr, FARMER J R, et al. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors[J]. Curr Cardiol Rep，2021，23(8):98. DOI：10.1007/s11886-021-01530-2.
[14]	ZHANG Y, ZHANG X L, LI W L, et al. Biomarkers and risk factors for the early prediction of immune-related adverse events：a review[J]. Hum Vaccin Immunother，2022，18(1):2018894. DOI：10.1080/21645515.2021.2018894.
[15]	LAL J C, BROWN S A, COLLIER P, et al. A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors[J]. Cardiooncology，2021，7(1):19. DOI：10.1186/s40959-021-00106-x.
[16]	WONG S K, NEBHAN C A, JOHNSON D B. Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy[J]. Front Immunol，2021，12:786046. DOI：10.3389/fimmu.2021.786046.
[17]	PIROZZI F, POTO R, ARAN L, et al. Cardiovascular toxicity of immune checkpoint inhibitors：clinical risk factors[J]. Curr Oncol Rep，2021，23(2):13. DOI：10.1007/s11912-020-01002-w.
[18]	LEITER A, CARROLL E, DE ALWIS S, et al. Metabolic disease and adverse events from immune checkpoint inhibitors[J]. Eur J Endocrinol，2021，184(6):857-865. DOI：10.1530/eje-20-1362.
[19]	OKADA N, MATSUOKA R, SAKURADA T, et al. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer：a single-institution retrospective study[J]. Sci Rep，2020，10(1):13773. DOI：10.1038/s41598-020-70743-2.
[20]	TANG S Q, TANG L L, MAO Y P, et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer：a pooled analysis of 23 clinical trials and 8，436 patients[J]. Cancer Res Treat，2021，53(2):339-354. DOI：10.4143/crt.2020.790.
[21]	WOOD L S, MOLDAWER N P, LEWIS C. Immune checkpoint inhibitor therapy：key principles when educating patients[J]. Clin J Oncol Nurs，2019，23(3):271-280. DOI：10.1188/19.CJON.271-280.

免疫检查点抑制剂致多系统免疫相关不良事件的诊疗思路

Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 3

参考文献 21

相关文章 15

编辑推荐

Metrics

留言

[1]	李孟野, 姜一农. 可溶性肾素前体受体在多系统疾病中的研究进展[J]. 中国全科医学, 2024, 27(18): 2295-2300.
[2]	高歌, 张鑫越, 冯玉华, 窦婧予, 吴雪莹, 程根阳. 激素治疗慢性肾脏病进展高风险IgA肾病患者的预后分析——一项回顾性研究[J]. 中国全科医学, 2024, 27(06): 692-698.
[3]	张懂理, 沈冲, 张卫川, 陈海滨, 赵建军. 程序性死亡因子1/程序性死亡因子1配体抑制剂治疗肾细胞癌有效性及安全性的Meta分析[J]. 中国全科医学, 2023, 26(30): 3815-3822.
[4]	饶玉凤, 蒙丽恒, 周嘉, 梁杏欢, 黄振兴, 秦映芬. "社会性别男性"先天性肾上腺皮质增生症合并肾上腺巨大占位一例并文献复习[J]. 中国全科医学, 2023, 26(21): 2690-2694.
[5]	陈璐璐, 张利苹, 李静文, 董文杰, 吴欣爱. 程序性死亡受体1抑制剂联合呋喹替尼后线治疗转移性结直肠癌的临床疗效和安全性研究[J]. 中国全科医学, 2023, 26(18): 2262-2267.
[6]	常俊佩, 陈露, 吴通, 赵晓丽, 段方方, 刘丹娜, 孔天东. 免疫检查点抑制剂相关内分泌不良反应的发生及处理：一项单中心真实世界研究[J]. 中国全科医学, 2023, 26(17): 2095-2101.
[7]	宋平安, 陈晓亮, 姚远, 高瑾, 杨洋, 崔洪春, 张毅. 程序性死亡蛋白-1抑制剂单药治疗老年晚期非小细胞肺癌患者的疗效及安全性研究[J]. 中国全科医学, 2023, 26(02): 241-247.
[8]	洪子强, 金大成, 白向豆, 崔百强, 苟云久. 多原发肺癌诊断与治疗的最新研究进展[J]. 中国全科医学, 2022, 25(27): 3435-3442.
[9]	徐金发, 宋文灿, 郑中显, 鲍瑜, 华高艳, 蔡清, 侍伟伟, 章秀芳, 张建华, 童舟, 夏国安, 刘飞, 刘林涛, 肖克胜. 国产细胞程序性死亡受体1抑制剂卡瑞利珠单抗联合阿帕替尼一线治疗中晚期原发性肝癌的疗效研究[J]. 中国全科医学, 2022, 25(26): 3258-3262.
[10]	秦克, 李同林, 宫帅, 江美芳. 血清miR-210、miR-181a表达水平与慢性阻塞性肺疾病稳定期患者糖皮质激素治疗效果的关系及其预测价值研究[J]. 中国全科医学, 2022, 25(24): 3013-3017.
[11]	陈泽霖, 焦瑞, 武思羽, 王正, 周广伟, 李静, 刘新秀, 孟爱宏. 不同炎症表型AECOPD及ACO患者临床特征和糖皮质激素治疗反应比较[J]. 中国全科医学, 2022, 25(14): 1730-1735.
[12]	潘婷, 孙铁英. 抗肿瘤药物诱导的机化性肺炎的研究进展[J]. 中国全科医学, 2022, 25(14): 1772-1778.
[13]	杨蕾伊, 林桑, 谢其冰, 尹耕. 抗肿瘤PD-1和PD-L1治疗现状与免疫相关不良反应的机制探索[J]. 中国全科医学, 2022, 25(11): 1393-1398.
[14]	胡忠慧, 张茜, 李梅. 糖皮质激素性骨质疏松症的生物靶向药物治疗研究进展[J]. 中国全科医学, 2022, 25(06): 756-759.
[15]	付强，黄华丽，李爱民. 糖皮质激素对静脉丙种球蛋白非敏感性川崎病患儿自主神经功能变化的影响研究[J]. 中国全科医学, 2021, 24(5): 577-580.